Real‐World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1–3 Prior Lines of Therapy: Optum Database
ABSTRACT Background Early (often continuous) treatment of multiple myeloma (MM) with lenalidomide has become common practice, leading to an increase in lenalidomide‐refractory disease. Methods We report real‐world treatment patterns, health care resource utilization (HCRU), and outcomes for patients...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.71093 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849331463037648896 |
|---|---|
| author | Binod Dhakal Hermann Einsele Jordan M. Schecter William Deraedt Nikoletta Lendvai Ana Slaughter Carolina Lonardi Sandhya Nair Nirosha Elsem Varghese Jianming He Akshay Kharat Seina Lee Patricia Cost Ravi Potluri Mythili Koneru Nitin Patel Erika Florendo Paula Rodriguez‐Otero Kwee Yong |
| author_facet | Binod Dhakal Hermann Einsele Jordan M. Schecter William Deraedt Nikoletta Lendvai Ana Slaughter Carolina Lonardi Sandhya Nair Nirosha Elsem Varghese Jianming He Akshay Kharat Seina Lee Patricia Cost Ravi Potluri Mythili Koneru Nitin Patel Erika Florendo Paula Rodriguez‐Otero Kwee Yong |
| author_sort | Binod Dhakal |
| collection | DOAJ |
| description | ABSTRACT Background Early (often continuous) treatment of multiple myeloma (MM) with lenalidomide has become common practice, leading to an increase in lenalidomide‐refractory disease. Methods We report real‐world treatment patterns, health care resource utilization (HCRU), and outcomes for patients with lenalidomide‐refractory MM using data from Optum US Claims and Optum electronic health record (EHR) databases with index date from January 2016 to March 2022 (Claims) or December 2021 (EHR). Eligible patients had received 1–3 prior lines of therapy (LOT), including a proteasome inhibitor. Results A total of 1383 and 1597 patients with lenalidomide‐refractory disease were included from the Claims and EHR databases, respectively, with median ages of 72 and 68 years and mean Charlson Comorbidity Index scores of 4.0 and 3.1. The most common treatment combinations were daratumumab–pomalidomide–dexamethasone, daratumumab–bortezomib–dexamethasone, and pomalidomide–dexamethasone (~5% each). From LOT 2 to LOT 6, treatment attrition (patients who died or received no further treatment) was 95.2% to 95.9%. Median time to next treatment was 5.4 (Claims) and 5.9 months (EHR). Median OS was 35.2 (Claims) and 41.2 months (EHR). HCRU was consistent across LOT. Conclusions Patients with lenalidomide‐refractory MM who received 1–3 prior LOT had poor outcomes and moved quickly through available therapies, demonstrating an unmet need to improve outcomes in this difficult‐to‐treat patient population. |
| format | Article |
| id | doaj-art-4d08bccf4496449aab34d25ca5ef49b0 |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-4d08bccf4496449aab34d25ca5ef49b02025-08-20T03:46:34ZengWileyCancer Medicine2045-76342025-08-011415n/an/a10.1002/cam4.71093Real‐World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1–3 Prior Lines of Therapy: Optum DatabaseBinod Dhakal0Hermann Einsele1Jordan M. Schecter2William Deraedt3Nikoletta Lendvai4Ana Slaughter5Carolina Lonardi6Sandhya Nair7Nirosha Elsem Varghese8Jianming He9Akshay Kharat10Seina Lee11Patricia Cost12Ravi Potluri13Mythili Koneru14Nitin Patel15Erika Florendo16Paula Rodriguez‐Otero17Kwee Yong18Medical College of Wisconsin Milwaukee Wisconsin USAUniversitätsklinikum Würzburg Medizinische Klinik und Poliklinik II Würzburg GermanyJohnson & Johnson Raritan New Jersey USAJohnson & Johnson Beerse BelgiumJohnson & Johnson Raritan New Jersey USACilag GmbH International Zug SwitzerlandJohnson & Johnson Buenos Aires ArgentinaJohnson & Johnson Beerse BelgiumJohnson & Johnson Beerse BelgiumJohnson & Johnson Raritan New Jersey USAJohnson & Johnson Horsham Pennsylvania USAJohnson & Johnson Raritan New Jersey USAJohnson & Johnson Raritan New Jersey USAPutnam Associates New York New York USALegend Biotech USA Inc. Somerset New Jersey USALegend Biotech USA Inc. Somerset New Jersey USALegend Biotech USA Inc. Somerset New Jersey USAClínica Universidad de Navarra CIMA, CIBERONC, IDISNA Pamplona SpainUniversity College London Cancer Institute London UKABSTRACT Background Early (often continuous) treatment of multiple myeloma (MM) with lenalidomide has become common practice, leading to an increase in lenalidomide‐refractory disease. Methods We report real‐world treatment patterns, health care resource utilization (HCRU), and outcomes for patients with lenalidomide‐refractory MM using data from Optum US Claims and Optum electronic health record (EHR) databases with index date from January 2016 to March 2022 (Claims) or December 2021 (EHR). Eligible patients had received 1–3 prior lines of therapy (LOT), including a proteasome inhibitor. Results A total of 1383 and 1597 patients with lenalidomide‐refractory disease were included from the Claims and EHR databases, respectively, with median ages of 72 and 68 years and mean Charlson Comorbidity Index scores of 4.0 and 3.1. The most common treatment combinations were daratumumab–pomalidomide–dexamethasone, daratumumab–bortezomib–dexamethasone, and pomalidomide–dexamethasone (~5% each). From LOT 2 to LOT 6, treatment attrition (patients who died or received no further treatment) was 95.2% to 95.9%. Median time to next treatment was 5.4 (Claims) and 5.9 months (EHR). Median OS was 35.2 (Claims) and 41.2 months (EHR). HCRU was consistent across LOT. Conclusions Patients with lenalidomide‐refractory MM who received 1–3 prior LOT had poor outcomes and moved quickly through available therapies, demonstrating an unmet need to improve outcomes in this difficult‐to‐treat patient population.https://doi.org/10.1002/cam4.71093health care resource utilizationmultiple myelomareal‐world outcomesrefractory |
| spellingShingle | Binod Dhakal Hermann Einsele Jordan M. Schecter William Deraedt Nikoletta Lendvai Ana Slaughter Carolina Lonardi Sandhya Nair Nirosha Elsem Varghese Jianming He Akshay Kharat Seina Lee Patricia Cost Ravi Potluri Mythili Koneru Nitin Patel Erika Florendo Paula Rodriguez‐Otero Kwee Yong Real‐World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1–3 Prior Lines of Therapy: Optum Database Cancer Medicine health care resource utilization multiple myeloma real‐world outcomes refractory |
| title | Real‐World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1–3 Prior Lines of Therapy: Optum Database |
| title_full | Real‐World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1–3 Prior Lines of Therapy: Optum Database |
| title_fullStr | Real‐World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1–3 Prior Lines of Therapy: Optum Database |
| title_full_unstemmed | Real‐World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1–3 Prior Lines of Therapy: Optum Database |
| title_short | Real‐World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1–3 Prior Lines of Therapy: Optum Database |
| title_sort | real world treatment patterns and outcomes in patients with relapsed refractory multiple myeloma and 1 3 prior lines of therapy optum database |
| topic | health care resource utilization multiple myeloma real‐world outcomes refractory |
| url | https://doi.org/10.1002/cam4.71093 |
| work_keys_str_mv | AT binoddhakal realworldtreatmentpatternsandoutcomesinpatientswithrelapsedrefractorymultiplemyelomaand13priorlinesoftherapyoptumdatabase AT hermanneinsele realworldtreatmentpatternsandoutcomesinpatientswithrelapsedrefractorymultiplemyelomaand13priorlinesoftherapyoptumdatabase AT jordanmschecter realworldtreatmentpatternsandoutcomesinpatientswithrelapsedrefractorymultiplemyelomaand13priorlinesoftherapyoptumdatabase AT williamderaedt realworldtreatmentpatternsandoutcomesinpatientswithrelapsedrefractorymultiplemyelomaand13priorlinesoftherapyoptumdatabase AT nikolettalendvai realworldtreatmentpatternsandoutcomesinpatientswithrelapsedrefractorymultiplemyelomaand13priorlinesoftherapyoptumdatabase AT anaslaughter realworldtreatmentpatternsandoutcomesinpatientswithrelapsedrefractorymultiplemyelomaand13priorlinesoftherapyoptumdatabase AT carolinalonardi realworldtreatmentpatternsandoutcomesinpatientswithrelapsedrefractorymultiplemyelomaand13priorlinesoftherapyoptumdatabase AT sandhyanair realworldtreatmentpatternsandoutcomesinpatientswithrelapsedrefractorymultiplemyelomaand13priorlinesoftherapyoptumdatabase AT niroshaelsemvarghese realworldtreatmentpatternsandoutcomesinpatientswithrelapsedrefractorymultiplemyelomaand13priorlinesoftherapyoptumdatabase AT jianminghe realworldtreatmentpatternsandoutcomesinpatientswithrelapsedrefractorymultiplemyelomaand13priorlinesoftherapyoptumdatabase AT akshaykharat realworldtreatmentpatternsandoutcomesinpatientswithrelapsedrefractorymultiplemyelomaand13priorlinesoftherapyoptumdatabase AT seinalee realworldtreatmentpatternsandoutcomesinpatientswithrelapsedrefractorymultiplemyelomaand13priorlinesoftherapyoptumdatabase AT patriciacost realworldtreatmentpatternsandoutcomesinpatientswithrelapsedrefractorymultiplemyelomaand13priorlinesoftherapyoptumdatabase AT ravipotluri realworldtreatmentpatternsandoutcomesinpatientswithrelapsedrefractorymultiplemyelomaand13priorlinesoftherapyoptumdatabase AT mythilikoneru realworldtreatmentpatternsandoutcomesinpatientswithrelapsedrefractorymultiplemyelomaand13priorlinesoftherapyoptumdatabase AT nitinpatel realworldtreatmentpatternsandoutcomesinpatientswithrelapsedrefractorymultiplemyelomaand13priorlinesoftherapyoptumdatabase AT erikaflorendo realworldtreatmentpatternsandoutcomesinpatientswithrelapsedrefractorymultiplemyelomaand13priorlinesoftherapyoptumdatabase AT paularodriguezotero realworldtreatmentpatternsandoutcomesinpatientswithrelapsedrefractorymultiplemyelomaand13priorlinesoftherapyoptumdatabase AT kweeyong realworldtreatmentpatternsandoutcomesinpatientswithrelapsedrefractorymultiplemyelomaand13priorlinesoftherapyoptumdatabase |